ANIXAnixa Biosciences Inc
$3.39
$0.18
(5.14%)
Closed $3.32
$0.07
(2.11%)
After Hours
EarningsSep 10
Mkt Cap$119.08M
Vol258,323.00
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology PR Newswire SAN JOSE, Calif., July 14, 2026 Notice of...
PR Newswire
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date PR Newswire SAN JOSE, Calif., July 6, 2026 Multiple Patients...
PR Newswire
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 PR Newswire SAN JOSE, Calif., June 29, 2026 Composition of...
PR Newswire
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Anixa Biosciences Reports Positive Data from Completed Breast...
PR Newswire
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
Zacks
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in...
PR Newswire
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance PR Newswire SAN JOSE, Calif...
PR Newswire
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy PR Newswire SAN JOSE, Calif., May...
PR Newswire
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV PR...
PR Newswire
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology PR...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest ANIX News
ViewAnixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
PR Newswire
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
PR Newswire
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
PR Newswire
Advertisement|Remove ads.